Last reviewed · How we verify
Angiogenic Cell Precusors
Angiogenic Cell Precusors is a Cell therapy Biologic drug developed by TheraVitae Ltd.. It is currently in Phase 1 development.
Autologous cell therapy designed to promote angiogenesis and neovascularization in ischemic tissues.
Angiogenic Cell Precursors (ACPs) are being studied as a potential treatment for Congestive Heart Failure and Angina Pectoris through intracoronary administration. ACPs are autologous cells, meaning they are derived from the patient's own body, and are administered via a coronary artery bypass grafting (CABG) procedure.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Angiogenic Cell Precusors |
|---|---|
| Sponsor | TheraVitae Ltd. |
| Drug class | Cell therapy |
| Modality | Biologic |
| Phase | Phase 1 |
Mechanism of action
The therapy utilizes patient-derived cells with angiogenic potential to stimulate the formation of new blood vessels in damaged or ischemic tissues. These cells are intended to secrete pro-angiogenic factors and potentially differentiate to support vascular repair and tissue regeneration.
Approved indications
Common side effects
Key clinical trials
- Vescell(TM) for the Treatment of Patients With Severe Anginal Syndrome With or Without Heart Failure (PHASE1, PHASE2)
- ACPs Combined With CABG in Patients With CHF (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Angiogenic Cell Precusors CI brief — competitive landscape report
- Angiogenic Cell Precusors updates RSS · CI watch RSS
- TheraVitae Ltd. portfolio CI
Frequently asked questions about Angiogenic Cell Precusors
What is Angiogenic Cell Precusors?
How does Angiogenic Cell Precusors work?
Who makes Angiogenic Cell Precusors?
What drug class is Angiogenic Cell Precusors in?
What development phase is Angiogenic Cell Precusors in?
Related
- Drug class: All Cell therapy drugs
- Manufacturer: TheraVitae Ltd. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing